Medios AG

M&A Activity • Aug 17, 2017

News Details

Corporate | 17 August 2017 10:12

Medios AG: Strategic partner purchases equity stake in Medios AG

DGAP-News: Medios AG / Key word(s): Alliance/Miscellaneous

17.08.2017 / 10:12

The issuer is solely responsible for the content of this announcement.

---

Corporate News

Strategic partner purchases equity stake in Medios AG

– Pharmaceutical wholesaler Cranach Pharma GmbH purchases 500,000 Medios shares, around four percent of the share capital

– Transaction strengthens partnership and lays the foundation for further synergies in the Specialty Pharma business

Berlin, 17 August 2017 – Cranach Pharma GmbH, a strategic partner of Medios AG and a pharmaceutical wholesaler from Hamburg, has purchased 500,000 shares in Medios AG. That corresponds to around four percent of the share capital of Medios AG, which has a total of 12,421,836 shares. The shares were purchased at the current price of EUR 9.75 each and originate from the holdings of Manfred Schneider, the founder and CEO of Medios AG.

Manfred Schneider, CEO of Medios AG: “The purchase of the Medios shares by Cranach Pharma strengthens our successful strategic partnership and lays the foundation for further synergies in the Specialty Pharma business. Cranach Pharma supplies pharmaceuticals to speciality pharmacies throughout Germany. Together with Cranach Pharma, we have a relevant share in the fields of neurology, rheumatism, multiple sclerosis, HIV, oncology and ophthalmology.”

In the future, an intensive knowledge transfer is intended to accelerate the development of certain business areas. While in this respect Medios brings know-how in the field of oncology and HIV in particular, Cranach Pharma will contribute its expertise mainly in the fields of neurology, immunology, haemophilia and endocrinology.

About Medios AG

Medios is one of the leading competency partners and solutions providers for specialty pharmaceuticals in Germany. These are medicines for patients with rare or chronic diseases such as cancer, HIV and hepatitis, whose personalized therapy is often tedious and cost-intensive due to their individual requirements.

With our subsidiaries Medios Pharma, Medios Manufaktur and Medios Digital we connect individual market players to form cooperating partners. Our goal is to provide partners and customers with integrated solutions along the value chain, ensuring optimal patient care.

Medios AG is Germany’s first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard).

Contact

Kirchhoff Consult AG

Nikolaus Hammerschmidt

Borselstraße 20

22765 Hamburg

Germany

Telephone: +49 40 60918618

Fax: +49 40 60918660

Email: nikolaus.hammerschmidt@kirchhoff.de

www.kirchhoff.de

Disclaimer

This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.

---

17.08.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de

---

Language:	English
Company:	Medios AG
	Friedrichstraße 113a
	10117 Berlin
	Germany
Phone:	+49 30 232 566 – 800
Fax:	030 / 8321 8377
E-mail:	ir@medios.ag
Internet:	www.medios.ag
ISIN:	DE000A1MMCC8
WKN:	A1MMCC
Listed:	Regulated Market in Frankfurt (General Standard), Hamburg; Regulated Unofficial Market in Dusseldorf

End of News	DGAP News Service